Trimetazidine
- Generic Name
- Trimetazidine
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O3
- CAS Number
- 5011-34-7
- Unique Ingredient Identifier
- N9A0A0R9S8
- Background
Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.
Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems. The increased intracellular calcium decreases contractility. It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate ischemic injury. However, evidence for this mechanism is controversial.
Trimetazidine is not FDA approved. However, it has been approved in France since 1978.
- Indication
Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.
- Associated Conditions
- Angina Pectoris, Chronic Stable Angina Pectoris, Tinnitus, Vertigo, Decreased visual acuity caused by Vascular Disorders
Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- HCC
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 300
- Registration Number
- NCT03278444
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Treatment of Intermediate-stage Hepatocellular Carcinoma
- Conditions
- HCC
- Interventions
- Device: Basic drugs therapy of HCC by TACE
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 300
- Registration Number
- NCT03274427
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
- Conditions
- Precapillary Pulmonary Hypertension
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 26
- Registration Number
- NCT03273387
- Locations
- 🇮🇩
National Cardiovascular Center Harapan Kita Hospital, Jakarta, Indonesia
Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization
- Conditions
- Coronary Artery Disease(CAD)
- Interventions
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Jun Li
- Target Recruit Count
- 440
- Registration Number
- NCT03072082
Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization
- Conditions
- Coronary Artery Disease(CAD)
- Interventions
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Jun Li
- Target Recruit Count
- 440
- Registration Number
- NCT03072121
Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT02826616
- Locations
- 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China
The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease
- Conditions
- Coronary Artery DiseaseMicrocirculationVascular Resistance
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Clinical Hospital Center Zemun
- Target Recruit Count
- 71
- Registration Number
- NCT02107144
- Locations
- 🇷🇸
Institute for cardiovascular diseases Dedinje, Belgrade, Serbia
Trimetazidine in Pulmonary Artery Hypertension
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Pontificia Universidad Catolica de Chile
- Target Recruit Count
- 25
- Registration Number
- NCT02102672
- Locations
- 🇨🇱
Hospital Clinico Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, Chile
Trimetazidine Therapy in Hypertrophic Cardiomyopathy
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- University College, London
- Target Recruit Count
- 90
- Registration Number
- NCT01696370
- Locations
- 🇬🇧
The Heart Hospital, UCLH, London, United Kingdom
Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease
- Conditions
- Coronary Artery DiseaseType II Diabetes Mellitus
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2006-01-26
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 30
- Registration Number
- NCT00282360
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.